Profusa, Inc.

Profusa, Inc., trading under the ticker NVAC, filed a Form 10-Q with the SEC on August 14, 2025, continuing its public reporting obligations following a completed SPAC merger. The company operates in the digital health and medical device sector, developing implantable biosensor technology designed for continuous, real-time monitoring of body chemistry, including tissue oxygenation and metabolic markers. Profusa's platform is aimed at advancing continuous physiological monitoring beyond traditional point-in-time diagnostics. The quarterly filing, bearing accession number 0001213900-25-076861, provides updated financial disclosures for the post-merger combined company. Investors and analysts seeking full deal history, sponsor data, and filing timelines for NVAC and hundreds of other SPACs can sign up for complete access at SpacDesk.